Candel Therapeutics, Inc. CADL
8.82 USD +0.70 (+8.62%)
At closeNov 3, 2026, 4:01 PM EST
8.82 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
8.19 Day range 8.86
4.35 52-week range 14.00
- YTD
- +56.11%
- 1 year
- +68.97%
Financial health
Altman Z-Score
2.45 Grey zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C-1 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 2
- P/E 1
- P/B 1
Valuation
P/E -7.8×
FY 2019 5y median -5.0× FY 2025
P/S 0.0×
FY 2019 5y median 0.0× FY 2025
P/B 5.8×
FY 2019 5y median 3.3× FY 2025
P/FCF -7.7×
FY 2019 5y median -6.1× FY 2025
EV/EBITDA -5.2×
FY 2019 5y median -1.8× FY 2025
EV/Sales 0.0×
FY 2019 5y median 0.0× FY 2025
FCF Yield -13.0%
FY 2019 5y median -16.3% FY 2025
Profitability
Gross Margin 0.0%
FY 2019 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2019 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2019 5y median 0.0% FY 2025
ROE -73.5%
FY 2019 5y median -73.5% FY 2025
ROIC -41.4%
FY 2019 5y median -41.8% FY 2025
ROA -30.5%
FY 2019 5y median -40.5% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2019 FY 2025
Operating Income -44.6%
FY 2019 FY 2025
EPS (diluted) 58.6%
FY 2019 FY 2025
Free Cash Flow -43.9%
FY 2019 FY 2025
Financial Health
Current Ratio 13.3×
FY 2019 5y median 12.8× FY 2025
Quick Ratio 13.3×
FY 2019 5y median 12.8× FY 2025
Debt / Equity 0.0×
FY 2019 5y median 0.2× FY 2025
Net Debt / EBITDA 3.3×
FY 2019 5y median 2.3× FY 2025
Interest Coverage -22.8×
FY 2019 5y median -16.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31